Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer
Interventions: DRUG: Neratinib
Sponsor: Chinese Academy of Medical Sciences